Body weight-loss effect of DPP4 inhibitors in established obese mice after 4-week treatment.

(A) To select each dosage for twice daily administration, plasma DPP4 inhibition was assessed 12 h after a single oral administration in HF-DIO mice. (B-E) After 4 week-administration of evogliptin, sitagliptin, vildagliptin, saxagliptin, or linagliptin twice daily by oral gavage in HF-DIO mice, (B) body weight, (C) fed plasma levels of active GLP-1, (D) insulin, and (E) fed blood glucose levels were determined (n = 5/group). #, P < 0.05 vs. lean control; *, P < 0.05 vs. HF-DIO control by one-way ANOVA; †, P < 0.05 vs. the baseline by RM two-way ANOVA.